Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children;Taşiyici çocuklardan izole edilen Moraxella catarrhalis suşlarinda BRO beta-laktamazlarin moleküler tiplendirilmesi

Mikrobiyoloji Bulteni

Volumn 38, Issue 4, 2004, Pages 335-340

  Köseoǧlu, Özgen ^a   Ergin, Alper ^a   Gürkan Aydin, Nazli ^a   Hasçelik, Gülşen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antimicrobial susceptibility; BRO beta lactamase; Moraxella catarrhalis

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; BRO BETA LACTAMASE; BRO BETA-LACTAMASE;

ARTICLE; CHILD; DRUG EFFECT; ENZYMOLOGY; FEMALE; HETEROZYGOTE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; NASOPHARYNX; PENICILLIN RESISTANCE;

AMPICILLIN RESISTANCE; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARRIER STATE; CHILD; FEMALE; HUMANS; MALE; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; NASOPHARYNX;

EID: 23844544111     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Faden H, Harabachi Y, Hong T, Wanda T: Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: Relationship to otitis media. J Infect Dis 1994, 169: 1312-1317.
2. McGregor K, Chang BJ, Mee BJ, Riley TV: Moraxella catarrhalis: Clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis 1998, 17: 219-234.
3. Greiner O, Day PJ, Altwegg M, Nadal D: Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR. J Clin Microbiol 2003, 41:1386-1390.
4. Bootsma HJ, Dijk HV, Verhoef J, Fleer A, Mooi FT: Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis. Antimicrob Agents Chemother 1996, 40: 966-972.
5. Verduin CM, Hol C, Fleer A, Dijk H and Belkum A: Morexalla catarrhalis: From emerging to established pathogen. Clin Microbiol Rev 2002, 15: 125-144.
6. National Committee for Clinical Laboratory Standards: Methods for dilution antibiotic susceptibility tests for bacteria that grow aerobically: Approved Standard M7-A5, 5th ed. 2000. NCCLS, Wayne, Pa.
7. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Supplemental tables. M100-S12, 2002. NCCLS, Wayne, Pa.
8. Plessis M: Rapid discrimination between BRO beta-lactamases from clinical isolates of Moraxella catarrhalis using restriction endonuclease analysis. Diagn Microbiol Infect Dis 2001, 39: 65-77.
9. Richter SS, Winokur PL, Brueggemann AB, et al: Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 US medical centers during 1994-1995 and 1997-1998. Antimicrob Agents Chemother 2000, 44: 444-446.
10. Boostma HJ, Dijk H, Vauterin P, Verhoef J, Mooi FR: Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: Evidence for transformation-mediated horizontal transfer. Mol Microbiol 2000, 36: 93-104.
11. Bandak SI, Turnak MR, Allen LD, et al: Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. Eur J Clin Microbiol Infect Dis 2001, 20: 55-60.
12. Doern GV, Jones RN, Pfaller MA, Kugler K: Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the Sentry antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1999, 43: 385-389.
13. Doern GV, Tubert TA: Effect of inoculum size on results of macrotube dilution susceptibility test with Branhamella catarrhalis. J Clin Microbiol 1987, 25: 1576-1578.
14. Yeo SF, Livermore DM: Effect of inoculum size on the in vitro susceptibility to beta-lactam antibiotics of Moraxella catarrhalis isolates of different beta-lactamase types. J Med Microbiol 1994, 40: 252-255.
15. Wallace RJ Jr, Nash DR, Steingrube VA: Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) calarrhalis. Am J Med 1990, 88: 46S-50S.
16. Wallace RJ Jr, Steingrube VA, Nash DR, et al: BRO beta-lactamases of Branhamella cataffhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactarnase transfer by conjugation in B.catarrhalis, M.nonliquefaciens and M.lacunata. Antimicrob Agents Chemother 1989, 33: 1845-1854.
17. Livermore DM: Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8: 557-584.
18. Levy F, Walker ES: BRO beta-lactamase alleles, antibiotic resistance and test of the BRO-1 selective replacement hypothesis in Moraxella catarrhalis. J Antimicrob Chemother 2004, 53: 371-374.
19. Stobberingh EE, VanEck HJ, Houben AW, Van Boven CPA: Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis. Drugs 1986, 31: 23-27.
20. Peerbooms PGH, Engelen MN, Stokman DAJ, et al: Nasopharyngeal carriage of potential bacterial pathogens related to day care attendance, with special reference to the molecular epidemiology of Haemophilus influenzae. J Clin Microbiol 2002, 40: 2832-2836.
21. Bootsma HJ, Aerts PC, Posthuma G, et al: Moraxella (Branhamella) catarrhalis BRO beta-lactamase: A lipoprotein of Gram-positive origin? J Bacteriol 1999, 181: 5090-5093.